Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 601–700 of 1,012
Gomez-Peralta, F., Escalada San Martín, F. J., Menéndez Torre, E., Mata Cases, M., Ferrer García, J. C., Ezkurra Loiola, P., Ávila Lachica, L., Fornos Pérez, J. A., Artola Menéndez, S., Álvarez-Guisasola, F., et al. (2018) · Endocrinología, Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 39
“753 53,0 Sobrepeso (IMC > 28kg/m(2)) y GPA > 108 mg/dL y ≤270 mg/dL 10,7 7,2 % 7,7% 0,7** (5-48) 0.”
Carbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 46
National Trends in Diabetes Medication Use in the United States: 2008 to 2015
Raval, A. D., & Vyas, A. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018815048 · Cited by 45
“Two studies published prior to 2015 showed no difference in the cardiovascular outcomes (cardiovascular death, myocardial infarction, ischemic stroke, hospitalization for unstable angina) among individuals receiving DPP-4 inhibitors as compared to placebo among diabetes patients.(22,23) However, the Saxagliptin Assess…”
ResultChoi, B., Kim, E., Kim, J.-E., Oh, S., Park, S.-O., Kim, S.-M., Choi, H., Song, J., & Chang, E. (2021) · Cells · doi:10.3390/cells10010057 · Cited by 43
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Standl, E., Erbach, M., & Schnell, O. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0353-y · Cited by 44
Howse, P. M., Chibrikova, L., Twells, L., Barrett, B. J., & Gamble, J. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.06.014 · Cited by 47
Wang, A., Tang, H., Zhang, N., & Feng, X. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109080 · Cited by 46
Shigiyama, F., Kumashiro, N., Miyagi, M., Iga, R., Kobayashi, Y., Kanda, E., Uchino, H., & Hirose, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12587 · Cited by 45
Wewer Albrechtsen, N. J., Albrechtsen, R., Bremholm, L., Svendsen, B., Kuhre, R. E., Poulsen, S. S., Christiansen, C. B., Jensen, E. P., Janus, C., Hilsted, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.051 · Cited by 40
“…(which elevate levels of endogenous GLP-1), all showing non-significant changes in acute pancreatitis rates as compared to placebo treatment control groups, albeit with a numerical imbalance in some studies (Scirica et al., 2013; White et al., 2013; Green et al., 2015; Bentley-Lewis et al., 2015).”
ResultEfficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Kosiborod, M., Gause‐Nilsson, I. A. M., Xu, J. L., Sonesson, C., & JOHNSSON, E. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.001 · Cited by 46
Lei, Y., Hu, L., Yang, G., Piao, L., Jin, M., & Cheng, X. W. (2017) · Circulation Journal · doi:10.1253/circj.cj-16-1326 · Cited by 45
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
“Dual antiplatelet treatment should be administered in T2DM patients following an ACS (for up to 12 months or even more).”
BackgroundMethodInfluentialLim, S. K., Eckel, R. H., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.013 · Cited by 48
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
McGuire, D. K., Marx, N., Johansen, O. E., Inzucchi, S. E., Rosenstock, J., & George, J. T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13645 · Cited by 42
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, W., Xu, L., Zhang, H., & Li, Y. (2022) · BMJ · doi:10.1136/bmj-2021-068882 · Cited by 50
Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges
Gore, M. O., McGuire, D. K., Lingvay, I., & Rosenstock, J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0607-7 · Cited by 48
Ryder, R. E. J. (2013) · Diabetic Medicine · doi:10.1111/dme.12301 · Cited by 41
Hupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
Alvarez, C., Lingvay, I., Vuylsteke, V., Koffarnus, R. L., & McGuire, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.143 · Cited by 46
“The EXAMINE trial evaluating the CVD effects of alogliptin was a multicenter, randomized, double-blind, placebo-controlled trial in 5,380 patients with T2DM and recent acute coronary syndromes (ACS).(72) Patients enrolled in the trial were randomized to receive alogliptin (N5 2,701) or placebo (N5 2,679) in addition t…”
MethodPotentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
Groeneveld, O. N., Kappelle, L. J., & Biessels, G. J. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12420 · Cited by 43
Son, J. W., & Kim, S. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.5.373 · Cited by 45
“This EXAMINE trial analysis showed that alogliptin does not increase HF morbidity or mortality in patients with type 2 diabetes or recent acute coronary syndrome, or worsen HF outcomes in patients with preexisting HF.”
BackgroundMethodResultInfluentialIhara, M., Asanuma, H., Yamazaki, S., Kato, H., Asano, Y., Shinozaki, Y., Mori, H., Minamino, T., Asakura, M., Sugimachi, M., et al. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00835.2014 · Cited by 42
“The recent large-scale clinical trials EXAMINE and SAVOR showed that alogliptin does not reduce the rate of hospitalization or death due to CVD in patients with diabetes mellitus (42, 47).”
BackgroundSitagliptin and pancreatic cancer risk in patients with type 2 diabetes
Tseng, C. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12570 · Cited by 39
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 50
Tanaka, A., Inoue, T., Kitakaze, M., Oyama, J.-I., Sata, M., Taguchi, I., Shimizu, W., Watada, H., Tomiyama, H., Ako, J., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0381-x · Cited by 43
Elgendy, I. Y., Mahmoud, A. N., Barakat, A. F., Elgendy, A. Y., Saad, M. S., Abu‐Zaid, A., Wayangankar, S. A., & Bavry, A. A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0208-x · Cited by 42
“and EXAMINE], the risk of hospitalization for heart failure was not increased with either sitagliptin or alogliptin, respectively [7, 8, 50].”
Wang, M.-T., Lin, S., Tang, P., Hung, W.-T., Cheng, C.-C., Yang, J.-S., Chang, H., Liu, C., Mar, G.-Y., & Huang, W. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0572-0 · Cited by 41
“ACEI: angiotensin‑converting enzyme inhibitor; ACS: acute coronary syn‑ drome; AMI: acute myocardial infarction; ARB: angiotensin receptor blocker; CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes; CCB: calcium channel blocker; CI: confidence interval; COPD: chr…”
BackgroundNovel therapies for diabetic kidney disease
Cherney, D. Z. I., & Bakris, G. L. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.005 · Cited by 48
Self-citationManagement Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review
Cehic, M. G., Nundlall, N., Greenfield, J. R., & Macdonald, P. S. (2018) · Journal of Transplantation · doi:10.1155/2018/1025893 · Cited by 43
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2017.12.003 · Cited by 47
Tanaka, M., Matsuo, Y., Yamakage, H., Masuda, S., Terada, Y., Muranaka, K., Wada, H., Hasegawa, K., Shimatsu, A., & Satoh‐Asahara, N. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.009 · Cited by 42
“[13] White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al.”
BackgroundAlogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0385-y · Cited by 45
“The proportion of patients with serum ALT or AST levels[3 times the upper limit of normal did not significantly differ between alogliptin and placebo recipients [56].”
BackgroundMethodResultInfluentialTreatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies
Lovshin, J. A., & Zinman, B. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.001 · Cited by 42
“The Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE) trial (50) was a doubleblind, noninferiority trial that enrolled 5380 patients with type 2 diabetes within 15 to 90 days of hospitalization for acute myocar…”
MethodSagara, M., Suzuki, K., Aoki, C., Tanaka, S., Taguchi, I., Inoue, T., & Aso, Y. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0396-3 · Cited by 43
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop, G. E., Zhong, J., Peters, M. C., Goud, A., Chen, Y., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 41
Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
Tanaka, A., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.019 · Cited by 42
The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
Secrest, M. H., Udell, J. A., & Filion, K. B. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.01.009 · Cited by 42
“16; Table 2) [10], satisfying the pre-specified non-inferiority margin of 1.”
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes
Garlo, K. G., White, W. B., Bakris, G. L., Zannad, F. M., Wilson, C., Kupfer, S., Vaduganathan, M., Morrow, D. A., Cannon, C. P., & Charytan, D. M. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05280517 · Cited by 40
Self-citationLeiter, L. A., Shestakova, M. V., & Satman, İ. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0331-8 · Cited by 43
Giugliano, D., Chiodini, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01047-0 · Cited by 43
Sharma, A., Vaduganathan, M., Ferreira, J. P., Liu, Y., Bakris, G. L., Cannon, C. P., White, W. B., & Zannad, F. M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012797 · Cited by 41
Self-citationRole of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 44
“events in T2DM patients with a history of recent acute coronary syndrome.(89) The CARMELINA (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Dia-”
BackgroundComparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE
Cornell, S. A. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2016.11.005 · Cited by 46
The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
Panchapakesan, U., & Pollock, C. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00443 · Cited by 39
“The EXAMINE study evaluated alogliptin use in patients with type 2 diabetes after acute coronary syndromes showed that there was no increase in the rates of MACE-plus (42).”
MethodInfluentialGlucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 43
“Although an increased signal for heart failure was not apparent in other trials, a class effect among incretins cannot be fully excluded and caution is required.(15) Still, because many traditional hypoglycemic agents are associated with fluid retention that is undesirable in the setting of heart failure, GLP-1 agonis…”
BackgroundVelez, M., Peterson, E. L., Wells, K., Swadia, T., Sabbah, H. N., Williams, L. K., & Lanfear, D. E. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.10.012 · Cited by 39
“Recently completed randomized controlled trials have shown that DPP-4 inhibitors saxagliptin and alogliptin do not have a significant impact on major adverse cardiac events related to atherosclerotic CV disease (14, 15).”
BackgroundKim, S. C., Glynn, R. J., Liu, J., Everett, B. M., & Goldfine, A. B. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0663-2 · Cited by 41
“Our finding of no increased CVD risk in DPP4i initiators as used in the community is consistent with RCT data on linagliptin, saxagliptin, and alogliptin [4, 11, 12, 25].”
ResultTeneligliptin: expectations for its pleiotropic action
Morishita, R., & Nakagami, H. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1000301 · Cited by 39
“In the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) study of 5380 T2DM patients who had experienced a recent acute coronary syndrome, alogliptin significantly reduced HbA1c [14].”
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient- Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., & Wender, R. C. (2015) · Cited by 44
Self-citationPositioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 43
“versus Standard of Care (EXAMINE) with alogliptin (23) and in the Trial Evaluating”
BackgroundInfluentialCardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 45
Consoli, A., Formoso, G., Baldassarre, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 37
“Among treatment for diabetes, thiazolidinediones have been shown to be associated with an increased risk of hospitalization for HF and a similar trend emerged from the safety CVOTs conducted with saxagliptin and (to a lesser extent) with alogliptin [35,36].”
ResultLamos, E. M., Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1626823 · Cited by 47
“Recently, in the subgroup analysis of the EXAMINE trial with alogliptin, an increased risk of CV death was observed in individuals with recent non-fatal CV event (specifically heart failure), compared with those who did not experience a CV event during the study [25].”
MethodInfluentialCobalt(II)-Catalyzed Alkoxycarbonylation of Aliphatic Amines via C–N Bond Activation
Li, C., Jiang, X., Lu, L., Xiao, W., & Wu, X. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b02534 · Cited by 39
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“This is supported by the finding that DPP-4 inhibitors, which are considered weight neutral [89,90], were even less effective on fasting lipid parameters [91–93].”
DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!
DeVries, J. H., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dci16-0035 · Cited by 39
Jung, M. J., & Kwon, S. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.536 · Cited by 38
Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Dardano, A., Miccoli, R., Bianchi, C., Daniele, G., & Prato, S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108112 · Cited by 40
Zannad, F., Stough, W. G., Lipicky, R. J., Tamargo, J., Bakris, G. L., Borer, J. S., Alonso García, M. D. L. A., Hadjadj, S., Koenig, W., Kupfer, S., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw007 · Cited by 38
“favourable effects of empagliflozin on weight loss, blood pressure, vascular markers, visceral adiposity, albuminuria, and plasma urate(8) or potential cardioprotective effects of incretin-based hormones).(5,6,14,31,32) Whether one or a combination of properties explains the positive effect of empagliflozin in EMPA-RE…”
BackgroundInfluentialSelf-citationJax, T. W., Stirban, A. O., Terjung, A., Esmaeili, H. A., Berk, A., Thiemann, S., CHILTON, R. J., von Eynatten, M., & Marx, N. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0493-3 · Cited by 40
Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study
Kim, N. H., Choi, J., Kim, N. H., Choi, K. M., Baik, S. H., Lee, J., & Kim, S. G. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.03.004 · Cited by 41
Kruse, B. C., & Vassar, M. B. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.007 · Cited by 39
SAIS Study Group, Kitao, N., Miyoshi, H., Furumoto, T., Ono, K., Nomoto, H., Miya, A., Yamamoto, K., Inoue, A., Tsuchida, K., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0607-6 · Cited by 38
Hanssen, N. M. J., & Jandeleit-Dahm, K. A. M. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119842339 · Cited by 40
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
Kaku, K., Kisanuki, K., Shibata, M., & Oohira, T. (2019) · Drug Safety · doi:10.1007/s40264-019-00857-8 · Cited by 42
Addressing Comorbidities in Heart Failure
Bavishi, A. A., & Patel, R. B. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.06.005 · Cited by 50
Ferreira, J. P., Sharma, A., Mehta, C. R., Bakris, G. L., Rossignol, P., White, W. B., & Zannad, F. M. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01729-3 · Cited by 42
Self-citationCardiac and Renovascular Complications in Type 2 Diabetes — Is There Hope?
Ingelfinger, J. R., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejme1607413 · Cited by 38
Wang, P., Huang, R., Lu, S., Xia, W., Sun, H., Sun, J. L., Cai, R., & Wang, S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0285-1 · Cited by 46
“Ten studies enrolled diabetic patients with a history of macrovascular disease [9, 10, 34–41], and HEART2D, EXAMIN, and DIGAMI1 only enrolled patients who had recently experienced adverse coronary events.”
BackgroundKadowaki, T., Marubayashi, F., Yokota, S., Katoh, M., & Iijima, H. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032249 · Cited by 37
“Prior studies have examined the long-term safety of saxagliptin (SAVORTIM53) [24] and alogliptin (EXAMINE) [25] in patients with a high risk of CVD.”
BackgroundSGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 44
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della‐Morte, D., Bellia, A., Daniele, N. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021646 · Cited by 39
“In addition, contrary to the results of the SAVOUR-TIMI 53 trials, the EXAMINE study indicated no increase in the risk of new HFH but a modest increase in the rate of hospitalization in patients without a history of HF [104].”
ResultIncretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 40
Khera, R., Schuemie, M. J., Lu, Y., Ostropolets, A., Chen, R., Hripcsak, G., Ryan, P. B., Krumholz, H. M., & Suchard, M. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057977 · Cited by 37
Gejl, M., Starup‐Linde, J., Thomsen, J. L. S., Gregersen, S., & Vestergaard, P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.096 · Cited by 39
“We report neutral outcomes in the DPP-4 inhibitor treated group consistentwith thefirst two studies onDPP-4 inhibitors and CVD events revealing that treatment with saxagliptin or alogliptin in patients with DM is not associated with improvements in cardiovascular risk [8,9].”
Tricco, A. C., Antony, J., Khan, P. A., Ghassemi, M., Hamid, J. S., Ashoor, H. M., Blondal, E., Soobiah, C., Yu, C. H. Y., Hutton, B., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005752 · Cited by 39
“One trial found that no differences were observed between a DPP-4 inhibitor and placebo regarding major cardiovascular events after 40 months follow-up.(36) The other trial found that after 2.”
BackgroundNew Developments in Diabetes Management: Medications of the 21st Century
Fonseca, V. A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.018 · Cited by 38
“A number of cardiovascular outcomes trials have been conducted with incretin agents, 2 of which have recently completed.(25,26) Contrary to study expectations based on a reduction in events from meta-analysis of short-term clinical trials, neither study demonstrated a reduction in events.”
Chang, Y., Chuang, L., Lin, J., Chen, S., Lai, M., & Chang, C. (2015) · Diabetic Medicine · doi:10.1111/dme.12800 · Cited by 37
Incretin-Based Therapy for Diabetes
Waldrop, G. E., Zhong, J., Peters, M. C., & Rajagopalan, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.058 · Cited by 39
“5 mg if GFR <60 ml/ min) versus placebo in acute coronary syndrome (ACS) (54).”
Gao, H. X., Regier, E. E., & Close, K. L. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12377 · Cited by 36
GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products
Guglielmi, V., & Sbraccia, P. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0352-y · Cited by 43
Bergmark, B. A., Cannon, C. P., White, W. B., Jarolím, P., Liu, Y., Bonaca, M. P., Zannad, F. M., & Morrow, D. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12905 · Cited by 41
“An independent clinical events committee adjudicated each component of the primary endpoint according to prespecified criteria.(32,33) Hospitalization for HF was additionally recorded and adjudicated.”
Self-citationTreatment of diabetic kidney disease: current and future targets
Kim, M. K. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.219 · Cited by 39
“[38] reported that linagliptin treatment, coupled with stable inhibition of the renal-angiotensin-aldosterone system, significantly reduced albuminuria in patients with diabetes, and that this was not attributable to a reduced blood glucose level or a lowering of blood pressure (BP) [36].”
BackgroundResultThe European Medicines Agency's approval of new medicines for type 2 diabetes
BLIND, E., Janssen, H., Dunder, K., & de Graeff, P. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13349 · Cited by 40
Gallwitz, B. (2018) · European Endocrinology · doi:10.17925/ee.2018.14.1.17 · Cited by 37
Bekki, M., Tahara, N., Tahara, A., Igata, S., Honda, A., Sugiyama, Y., Nakamura, T., Sun, J., Kumashiro, Y., Matsui, T., et al. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180515154555 · Cited by 39
Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
Almagthali, A., Alkhaldi, E. H., Alzahrani, A. S., Alghamdi, A. K., Alghamdi, W. Y., & Kabel, A. M. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.08.012 · Cited by 41
Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects
da Silva, J. C., Filho, J. D. S. R., Cavalcanti, C. A. J., Martins, A., & Salles, J. E. N. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00757-y · Cited by 41
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 38
Impaired glucose tolerance in acute pancreatitis
Kikuta, K., Masamune, A., & Shimosegawa, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i24.7367 · Cited by 36
Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes
Bonnet, F., & Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.004 · Cited by 40
“…P DPP-4is Interventional studies (RCTs) Scirica et al., 2013 [86] SAVOR-TIMI 53 2.1 Saxagliptin 157/8280 (1.9) 141/8212 (1.7) 1.11 (0.88–1.39) 0.38 White et al., 2013 [85] EXAMINE 1.5 Alogliptin Non-fatal stroke 29/2701 (1.1) 32/2679 (1.2) 0.91 (0.55–1.50) 0.71 Greene et al., 2015 [87] TECOS 3.0…”
InfluentialProgress in the treatment of diabetic cardiomyopathy, a systematic review
Shou, Y., Li, X. M., Fang, Q., Xie, A., Zhang, Y., Fu, X., Wang, M., Gong, W., Zhang, X., & Yang, D. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1177 · Cited by 37
“63 Furthermore, in animal experiments, DPP-4 inhibitors have been shown to exert pleiotropic effects on heart fail - ure.”
BackgroundSheng‐Kai, K., Lo, J., Kyttaris, V. C., Tsokos, G. C., & Costenbader, K. H. (2024) · Arthritis & Rheumatology · doi:10.1002/art.43037 · Cited by 39
Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
Jarvis, C. I., Cabrera, A., & Charron, D. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504076 · Cited by 40
Type 2 Diabetes Medication Review
Sterrett, J., Bragg, S. W., & Weart, C. W. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.01.019 · Cited by 42
“s EXAMINE trial evaluated patients with recent acute coronary syndrome within the previous 15-90 days and found no difference between alogliptin and placebo in the event rates of any of the cardiac ischemic outcomes over a mean of 18 months.(64) In summary, DPP-4 inhibitors that provide modest A1c reduction are genera…”
MethodHirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 39
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.